INVA
Innoviva IncNASDAQ
Healthcare • Biotechnology
Factor tilt: Small-Cap Value
$19.10-0.73%
Close Nov 6, 2026
- Market cap
- $1.41B
- 1 month
- -8.5%
- 3 months
- -7.6%
- 1 year
- +4.8%
- 52-week range
- $19.10$24.24
- Dividend, last 12 mo
- None in the last year
- Last ex-date
- Sep 8, 2015 · $0.25
- Short interest
- 10.7% of float7.3M shares · settled Oct 15, 2026 · +6.1% since Sep 30, 2026 · FINRA
Fundamentals · trailing 12 months to Sep 30, 2026
- Revenue
- $441.75M
- Net income
- $193.44M
- Free cash flow
- $181.39M
- Book value
- $1.14B
- Total debt
- $269.87M
- P/E
- 7.3×
- Price / sales
- 3.2×
- Price / book
- 1.2×
- FCF yield
- +12.9%
- Net margin
- +43.8%
EODHD (TTM) · as of Nov 6, 2026
End-of-day close from stored market data, not a live quote.
About Innoviva Inc
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI.
Read more
The company also markets GIAPREZA for increasing blood pressure in adults with septic or other distributive shock; XACDURO, a co-packaged for intravenous use for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter; XERAVA for the treatment of complicated intra-abdominal infections in adults; ZEVTERA an advanced-generation cephalosporin antibiotic for the treatment of staphylococcus aureus bacteremia, as well as with right-sided endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia; NUZOLVENCE for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents. In addition, the company develops bacteriophages with potential use in a range of infectious and other serious diseases. It has a strategic partnership with Sarissa Capital Management LP; and LABA Collaboration Agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
- Website
- inva.com
- Headquarters
- Burlingame, CA, United States
- Employees
- 159
- Listed
- Oct 5, 2004
- Fiscal year ends
- December
Company profile from EODHD, stored Nov 7, 2026.
Quarterly results
The last 8 fiscal quarters as reported (EODHD). Year over year compares the same quarter a year earlier.
| Quarter | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Sep 2026filed Nov 4, 2026 | $106.1M | -1.6% | 79.5% | $42.2M | -$73.9M |
| Jun 2026filed Aug 5, 2026 | $119.6M | +19.3% | 75.8% | $50.9M | -$83.4M |
| Mar 2026filed May 6, 2026 | $98.0M | +10.6% | 77.4% | $38.2M | $186.6M |
| Dec 2025filed Feb 25, 2026 | $118.0M | +28.6% | 64.1% | $39.0M | $164.2M |
| Sep 2025filed Nov 5, 2025 | $107.8M | +20.4% | 76.1% | $34.6M | $89.9M |
| Jun 2025filed Aug 6, 2025 | $100.3M | -3.0% | 89.4% | -$48.8M | $63.7M |
| Mar 2025filed May 7, 2025 | $88.6M | +14.4% | 90.0% | -$41.4M | -$46.6M |
| Dec 2024filed Feb 26, 2025 | $91.8M | +7.0% | 92.2% | $43.1M | $20.3M |
Fiscal years · last 6
| Fiscal year | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Dec 2025filed Feb 25, 2026 | $425.1M | +18.5% | 72.3% | $163.7M | $271.2M |
| Dec 2024filed Feb 26, 2025 | $358.7M | +15.5% | 89.8% | $166.9M | $23.4M |
| Dec 2023filed Feb 29, 2024 | $310.5M | -6.3% | 86.3% | $113.9M | $179.7M |
| Dec 2022filed Feb 28, 2023 | $331.3M | -15.4% | 95.8% | $207.0M | $213.9M |
| Dec 2021filed Feb 28, 2022 | $391.9M | +16.4% | — | $375.1M | $265.9M |
| Dec 2020filed Feb 25, 2021 | $336.8M | +29.0% | — | $321.1M | $224.4M |
Short-interest history
FINRA reports open short positions for a settlement date. The publication date is later. These are reported positions, with a separate date for each observation.
Compare the reported short exposure around the dates you bought, sold or watched INVA. A long position benefits from price rises; a short position benefits from falls. A change in these counts does not predict either move.
Settlement Oct 15, 2026
7,265,728 shares short
+420,243 shares (+6.1%) vs Sep 30, 2026
10.7% of the stored float. Published Oct 26, 2026.
Settlement Sep 30, 2026
6,845,485 shares short
-298,780 shares (-4.2%) vs Sep 15, 2026
10.1% of the stored float. Published Oct 9, 2026.
Settlement Sep 15, 2026
7,144,265 shares short
+203,928 shares (+2.9%) vs Aug 31, 2026
Share of float unavailable. Published Sep 24, 2026.
Settlement Aug 31, 2026
6,940,337 shares short
+76,060 shares (+1.1%) vs Aug 14, 2026
10% of the stored float. Published Sep 10, 2026.
Settlement Aug 14, 2026
6,864,277 shares short
-27,804 shares (-0.4%) vs Jul 31, 2026
9.9% of the stored float. Published Aug 25, 2026.
Settlement Jul 31, 2026
6,892,081 shares short
-123,816 shares (-1.8%) vs Jul 15, 2026
10% of the stored float. Published Aug 11, 2026.
Change = this settlement’s shares short − the previous recorded settlement’s shares short; percentage change divides by that earlier count. A zero earlier count has no percentage change. Split-spanning counts are left uncompared. Float percentages use the stored settlement observation, not today’s float.
Source: stored FINRA equity short-interest records, up to six settlements from the last 240 days. FINRA data and reporting dates · How to read short interest
Dividends and stock splits
See the recorded cash amounts and dates behind INVA’s income, and the splits that change its share count. Dates below are stored event records, not confirmation of a payment to your account.
Cash-dividend records
The newest stored ex-date is Sep 8, 2015. These are historical records; a current dividend schedule is unavailable.
USD 0.25 per share
Ex-dividend date: Sep 8, 2015
Recorded pay date: Sep 30, 2015 (past date)
Cash dividend · Polygon event record
USD 0.25 per share
Ex-dividend date: Jun 10, 2015
Recorded pay date: Jun 30, 2015 (past date)
Cash dividend · Polygon event record
USD 0.25 per share
Ex-dividend date: Mar 10, 2015
Recorded pay date: Mar 31, 2015 (past date)
Cash dividend · Polygon event record
USD 0.25 per share
Ex-dividend date: Nov 21, 2014
Recorded pay date: Dec 23, 2014 (past date)
Cash dividend · Polygon event record
USD 0.25 per share
Ex-dividend date: Aug 26, 2014
Recorded pay date: Sep 18, 2014 (past date)
Cash dividend · Polygon event record
Up to six Polygon cash-dividend events, including recorded ex-dates within the next 120 days. Amounts retain their recorded currency and decimal precision. Historical amounts are not restated to a common split basis, annualized, or converted to dollars.
For a long holding, compare the ex-date with when you held the shares and check the pay date against your broker’s cash history. Owning the stock today does not establish past entitlement. For a short holding, a dividend can create a payment obligation to the share lender.
Ex-dates and special dividend rules · Short-sale dividend obligations · Dividend data definitions
Split history
1241 for 1000 · forward split
Effective Jun 3, 2014
Each 1000 pre-split shares become 1241 post-split shares.
Source: EODHD
Up to six stored split dates through Nov 7, 2026. Equivalent vendor ratios are combined; conflicting ratios are left out. This history may be incomplete.
A split changes the share count and per-share price basis; it does not by itself add investment value. Put your holding’s earlier and later share counts on the same basis before comparing them. This applies to both long shares and shares owed on a short position.
How stock splits workPortfolio context
Sign in to see your position size
We’ll show you if INVA is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
Smart money context
Holder IQ: MEDIUM
38 smart-money holders: institutions with a high Holder IQ
Q2 2026, filed Oct 30, 2026
Smart-money 13F trend: distributing (heavy)
Unlock crowding heatmapUnlock filer discoveryInsider context
Sentiment: unknown
No recent insider trades detected.
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
No directional recent-activity label is available. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Red flags: 7
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
No directional recent-activity label is available. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Largest 13-F holders · Q2 2026
309 filers reported a long position in INVA for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
The top 10 hold
52.7%
of the 74.6M shares 13-F filers reported
Moves vs Q1 2026
7 added3 trimmed
Net shares held
+2.9%
across the 10 holders with a comparable Q1 2026 book
| Rank | Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|---|
| 1 | BlackRock, Inc. | $262.4M · 11.6M shares | 11.6M | +2.2% |
| 2 | DIMENSIONAL FUND ADVISORS LP | $102.1M · 4.5M shares | 4.5M | +1.3% |
| 3 | VANGUARD PORTFOLIO MANAGEMENT LLC | $95.8M · 4.2M shares | 4.2M | -0.1% |
| 4 | RENAISSANCE TECHNOLOGIES LLC | $91.7M · 4M shares | 4M | -0.5% |
| 5 | STATE STREET CORP | $74.2M · 3.3M shares | 3.3M | +6.8% |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | $71.7M · 3.2M shares | 3.2M | +0.5% |
| 7 | MILLENNIUM MANAGEMENT LLC | $57.7M · 2.5M shares | 2.5M | +11.5% |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | $47.1M · 2.1M shares | 2.1M | +7.5% |
| 9 | SYSTEMATIC FINANCIAL MANAGEMENT LP | $46M · 2M shares | 2M | 0% |
| 10 | Boston Partners | $43.8M · 1.9M shares | 1.9M | +12.2% |
Sign in to see each holder’s Holder IQ, factor-adjusted Holder IQ and rank, and compare these holders with all scored filers. Available on every plan.
Sign in5% holder filings (13D / 13G)
Holders of more than 5% of INVA file with the SEC within days. A 13D holder may seek to influence the company; a 13G holder is passive. Each holder’s latest filing from the last three years.
| Filed | Holder | % of class |
|---|---|---|
| Oct 27, 2026 | BlackRock, Inc.13G · passive · amended | 15.4% |
| Jul 31, 2026 | VANGUARD CAPITAL MANAGEMENT LLC13G · passive | 5.01% |
| Apr 29, 2026 | VANGUARD PORTFOLIO MANAGEMENT LLC13G · passive | 5.79% |
| Mar 27, 2026 | VANGUARD GROUP INC13G · passive · amended | 0%under 5% |
Get the Full Analysis for INVA
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.